Loading
A phase 2 trial in colorectal cancer, run by Jiangsu HengRui Medicine Co., Ltd., not yet recruiting.
A Global Trial of Trastuzumab Rezetecan (SHR-A1811) in Combination With Chemotherapy and Bevacizumab as First-Line Treatment in Patients With Advanced Colorectal Cancer Expressing HER2 is a phase 2, randomised interventional study registered as NCT07796763 by Jiangsu HengRui Medicine Co., Ltd., with a registry enrolment figure of 48 participants, started 2026-11-01 and due to reach its primary completion in 2028-05-01. Interventions recorded: Trastuzumab Rezetecan (SHR-A1811) injection; high dose; Trastuzumab Rezetecan (SHR-A1811) injection; low dose. Conditions listed: Advanced Colorectal Cancer Expressing HER2. Primary outcome: Incidence of treatment-emergent adverse events; Determination of the recommended phase 3 dose. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed unresectable, recurrent, or metastatic colorectal adenocarcinoma that is HER2-positive". Sites: United States. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Jiangsu Hengrui Pharmaceuticals, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares HER2-amplified colorectal cancer, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Jiangsu Hengrui Pharmaceuticals, Colon cancer (adenocarcinoma of the colon), Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/